your market intelligence analyst
Search Results
21 results
Your search is now limited to «Atrial Fibrillation» expert search.
PR Newswire 10/12/2019 04:48
The wider Global ETNA-AF programme, which at present is the largest and most comprehensive repository of routine clinical practice data on the use, effectiveness, and safety of a single NOAC in patients with atrial fibrillation (AF), collected data from 24,962 patients in 2,242 sites in Japan , Korea/ Taiwan and Europe ...
Lancet 10/11/2019 12:17
Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) need oral anticoagulation to prevent cardioembolic events and antiplatelet therapy to prevent coronary events.1 In this context, three trials of rivaroxaban (PIONEER-AF PCI),2 dabigatran (RE-DUAL PCI),3 and apixaban (AUGUSTUS)4 showed that combining a non-vitamin K antagonist oral anticoagulant (NOAC) and a P2Y12 inhibitor, a strategy known as dual antithrombotic therapy (DAT), reduces bleeding compared with triple antithrombotic therapy (TAT) consisting of a vitamin K antagonist (VKA), a P2Y12 inhibitor, and aspirin.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.